Edwards Lifesciences Corp
EW
View Detailed Chart
76.050USD
-1.520-1.96%
Close 09/15, 16:00（ET）Quotes delayed by 15 min
44.71BMarket Cap
10.78P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.96%
5 Days
-5.19%
1 Month
-2.82%
6 Months
+9.76%
Year to Date
+2.73%
1 Year
+10.99%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-15Key Insights
The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
35
analysts
Buy
Current Rating
88.401
Target Price
+13.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 174.30.
Fairly Valued
The company’s latest PE is 10.91, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 528.14M shares, decreasing 3.77% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 69.74M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.
Ticker SymbolEW
CompanyEdwards Lifesciences Corp
CEOMr. Bernard J. Zovighian
Websitehttps://www.edwards.com
Related Instruments
-1.04%
-3.49%
-2.77%
-0.79%
-0.06%
+0.39%
+1.94%
+1.73%
-0.11%
+1.24%
+6.10%
-1.01%
+1.36%
-2.04%
+3.75%
-0.24%
-1.13%
+0.09%
+1.23%
+1.35%
